Literature DB >> 25056602

Effect of total dose and fraction size on survival of patients with locally recurrent nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a phase 2, single-center, randomized controlled trial.

Yun-Ming Tian1, Chong Zhao, Ying Guo, Ying Huang, Shao-Min Huang, Xiao-Wu Deng, Cheng-Guang Lin, Tai-Xiang Lu, Fei Han.   

Abstract

BACKGROUND: The optimal model of total dose and fraction size for patients with locally recurrent nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) remains unclear. The authors designed a randomized phase 2 clinical trial to investigate the efficacy of 2 different models, with the objective of determining an optimal model.
METHODS: Between January 2003 and December 2007, a total of 117 patients with locally recurrent nonmetastatic nasopharyngeal carcinoma were randomized to 2 different models of total dose and fraction size: group A (59 patients) received 60 gray in 27 fractions and group B (58 patients) received 68 gray in 34 fractions. Both groups received 5 daily fractions per week. All patients received IMRT alone.
RESULTS: The median follow-up was 25.0 months. The 5-year overall survival in group A was higher than that in group B (44.2% vs 30.3%; P =.06), and the local failure-free survival in group A was slightly lower than that in group B (63.7% vs 71.0%; P =.41). Severe late complications were the main cause of death. The incidences of mucosal necrosis and massive hemorrhage in patients in group B were significantly higher than those among patients in group A at 50.8% versus 28.8% (P =.02) and 31.0% versus 18.6% (P =.12), respectively. Tumor volume (P<.01) and model of total dose and fraction size (P =.03) were found to be significant factors for mucosal necrosis and massive hemorrhage.
CONCLUSIONS: Appropriately decreasing the total dose and increasing the fraction size can achieve local control similar to that achieved with a higher dose after IMRT; furthermore, it can improve overall survival by significantly reducing the incidence of severe late complications including mucosal necrosis and massive hemorrhage.
© 2014 American Cancer Society.

Entities:  

Keywords:  fraction size; intensity-modulated radiotherapy (IMRT); late complications; local recurrence; nasopharyngeal carcinoma; total dose

Mesh:

Year:  2014        PMID: 25056602     DOI: 10.1002/cncr.28934

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  [Influence of dose and fractionation in intensity modulated re-irradiation of patients with relapse of nasopharyngeal carcinoma: a randomized phase II study].

Authors:  Carsten Nieder
Journal:  Strahlenther Onkol       Date:  2015-02       Impact factor: 3.621

2.  Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma.

Authors:  Victor H F Lee; Dora L W Kwong; To-Wai Leung; Sherry C Y Ng; Ka-On Lam; Chi-Chung Tong; Chun-Kin Sze
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-10-13       Impact factor: 2.503

Review 3.  LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential.

Authors:  Christopher S Hong; Winson Ho; Chao Zhang; Chunzhang Yang; J Bradley Elder; Zhengping Zhuang
Journal:  Cancer Biol Ther       Date:  2015-04-21       Impact factor: 4.742

Review 4.  Prospective randomized clinical studies involving reirradiation : Lessons learned.

Authors:  Carsten Nieder; Johannes A Langendijk; Matthias Guckenberger; Anca L Grosu
Journal:  Strahlenther Onkol       Date:  2016-08-17       Impact factor: 3.621

5.  Outcomes of Recurrent Nasopharyngeal Carcinoma Patients Treated With Salvage Surgery: A Meta-Analysis.

Authors:  Yekai Feng; Zhimei Dai; Ruicheng Yan; Feng Li; Xiaosheng Zhong; Haoxin Ye; Caiqing Chen; Shaochong Fan; Cheng Qing; Yong Pan; Haiying Sun
Journal:  Front Oncol       Date:  2021-10-08       Impact factor: 6.244

6.  Ways to unravel the clinical potential of carbon ions for head and neck cancer reirradiation: dosimetric comparison and local failure pattern analysis as part of the prospective randomized CARE trial.

Authors:  Thomas Held; Thomas Tessonnier; Henrik Franke; Sebastian Regnery; Lukas Bauer; Katharina Weusthof; Semi Harrabi; Klaus Herfarth; Andrea Mairani; Jürgen Debus; Sebastian Adeberg
Journal:  Radiat Oncol       Date:  2022-07-08       Impact factor: 4.309

7.  Retreatment in locally recurrent nasopharyngeal carcinoma: Current status and perspectives.

Authors:  Sharon Shuxian Poh; Yoke Lim Soong; Kiattisa Sommat; Chwee Ming Lim; Kam Weng Fong; Terence Wk Tan; Melvin Lk Chua; Fu Qiang Wang; Jing Hu; Joseph Ts Wee
Journal:  Cancer Commun (Lond)       Date:  2021-05-06

Review 8.  Preserving the legacy of reirradiation: A narrative review of historical publications.

Authors:  Carsten Nieder; Johannes A Langendijk; Matthias Guckenberger; Anca L Grosu
Journal:  Adv Radiat Oncol       Date:  2017-02-28

9.  The challenge in treating locally recurrent T3-4 nasopharyngeal carcinoma: the survival benefit and severe late toxicities of re-irradiation with intensity-modulated radiotherapy.

Authors:  Yun-Ming Tian; Wei-Zeng Huang; Xia Yuan; Li Bai; Chong Zhao; Fei Han
Journal:  Oncotarget       Date:  2017-06-27

Review 10.  Recurrent Nasopharyngeal Cancer: Critical Review of Local Treatment Options Including Recommendations during the COVID-19 Pandemic.

Authors:  Michaela Svajdova; Marian Sicak; Pavol Dubinsky; Marek Slavik; Pavel Slampa; Tomas Kazda
Journal:  Cancers (Basel)       Date:  2020-11-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.